Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (9): 1067-1072.doi: 10.12092/j.issn.1009-2501.2023.09.014

Previous Articles     Next Articles

Research progress of nuclear factor erythroid 2-related factor 2 in pulmonary fibrosis

WANG Jie1, LI Long2, CHEN Feng1, LIU Shengfei1   

  1. 1The First Clinical Medical College of Lanzhou University, Lanzhou 730000, GanSu, China; 2Department of Respiratory Medicine, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China
  • Received:2023-03-23 Revised:2023-07-10 Online:2023-09-26 Published:2023-09-25

Abstract:

Pulmonary fibrosis is a common chronic interstitial lung disease. It is characterized by excessive deposition of extracellular matrix and remodeling of lung tissue structure, resulting in severe impairment of lung function. The cause of its pathogenesis is still unclear. Therefore, it is urgent to explore its pathogenesis and find new targets to combat pulmonary fibrosis. Studies have shown that nuclear factor erythroid 2-related factor 2 can maintain the body's redox homeostasis by regulating antioxidant genes and combining antioxidant response components, thereby protecting tissues and cells from oxidative stress. In recent years, many studies have proved that nuclear factor erythroid 2-related factor 2 can play an anti-fibrotic role by alleviating oxidative stress, inhibiting macrophage polarization, activating autophagy, inhibiting ferroptosis, and blocking epithelial-mesenchymal transition. This paper provides a brief review of the association and research progress of nuclear factor erythroid 2-related factor 2 with pulmonary fibrosis, with the aim of providing a new direction for the precise treatment of pulmonary fibrosis.

Key words: nuclear factor erythroid 2-related factor 2, autophagy, ferroptosis, epithelial-mesenchymal transition

CLC Number: